Analysts at Oppenheimer provided a review on Cue Biopharma, Inc. (NASDAQ:CUE) following the company’s recently released Q4 results, with a full 2021-year EPS coming in at $(1.41).

Management provided incremental clinical updates from ongoing trials of CUE-101 in HPV+ HNSCC. Notably, a previously unconfirmed PR in the CUE-101 + pembrolizumab combination trial has been confirmed, and the analysts believe trends emerging from the trial’s updated spider plot hint at dose-dependent and durable efficacy.

In the second half of the year, management plans to meet with the FDA to define a registrational pathway in late-line HNSCC, and Cue is preparing to advance a second ImmunoSTAT, CUE-102, into the clinic soon.

The analysts lowered their price target on the company’s shares to $26 from $32 as they have extended CUE-101’s timeline in their model. Outperform rating was maintained.